Erythrocytes catechol-O-methyl transferase activity is up-regulated after a 3-month treatment by entacapone in parkinsonian patients

Clinical Neuropharmacology

Volumn 34, Issue 1, 2011, Pages 21-23

  Maltête, David ^a   Cottard, Anne Marie ^a   Mihout, Bruno ^a   Costentin, Jean ^a  

^a ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

catechol O methyl transferase; entacapone; Parkinson disease

Indexed keywords

CATECHOL METHYLTRANSFERASE; DOPA DECARBOXYLASE INHIBITOR; ENTACAPONE; LEVODOPA;

AGED; ARTICLE; CLINICAL ARTICLE; ENZYME ACTIVITY; ERYTHROCYTE; FEMALE; HUMAN; LONG TERM CARE; MALE; PARKINSONISM; PRIORITY JOURNAL; UPREGULATION;

AGED; ANTIPARKINSON AGENTS; CATECHOL O-METHYLTRANSFERASE; CATECHOLS; ENZYME INHIBITORS; ERYTHROCYTE COUNT; ERYTHROCYTES; FEMALE; HUMANS; MALE; MIDDLE AGED; NITRILES; PARKINSON DISEASE; TIME FACTORS; UP-REGULATION;

EID: 79551576070     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e318205dff7     Document Type: Article

References (15)

1. Männistö PT, Kaakkola S. Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev 1999;51: 593-628.
2. Jorga K, Fotteler B, Sedek G, et al. The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulation. J Neurol 1998;245:223-230.
3. Keränen T, Gordin A, Karlsson M, et al. Inhibition of soluble catechol-O-methyltransferase and single dose pharmacokinetics after oral and intravenous administration of entacapone. Eur J Clin Pharmacol 1994;46:1551-1557.
4. Tuomainen P, Reenilä I, Männisto PT. Validation of assay of catechol-O-methyltransferase activity in human erythrocytes. JPharm Biomed Anal 1996;14:515-523.
5. Guldberg HC, Marsden CA. Catechol-O-methyltransferase: pharmacological aspects and physiological role. Pharmacol Rev 1975;27:135-206.
6. Baldessarini RJ. Neuropharmacology of S-adenosyl-L-methionine. Am J Med 1987;83:95-103.
7. Lam LKT. Effects of butylated hydroxyanisole on glutathione S-transferase and catechol-O-methyltransferase activities in Syrian golden hamsters. Biochem Pharmacol 1988;37:3011-3016.
8. Li Y, Zhang G, Suzuki H, et al. Actions of dipyridamole on endogenous and exogenous noradrenaline in the dog mesenteric vein. Br J Pharmacol 1991;102:51-56.
9. Fatemi SH, Folsom TD. Catechol-O-methyltransferase gene is regulation in rat frontal cortex. Mol Psychiatry 2007;12:322-323.
10. Chen ML, Chen CH. Chronic antipsychotics treatment regulates MAOA, MAOB and COMT gene expression in rat frontal cortex. J Psychiatr Res 2007;41:57-62.
11. Dingemanse J, Jorga K, Zürcher G, et al. Multiple-dose clinical pharmacology of the catechol-O-methyltransferase inhibitor tolcapone in elderly subjects. Eur J Clin Pharmacol 1996;50:47-55.
12. Gordin A, Kaakkola S, Teräväinen H. Clinical advantages of COMT inhibition with entacapone\a review. J Neural Transm 2004;111:1343-1363.
13. Larsen JP, Worm-Petersen J, Siden A, et al. The tolerability and efficacy of entacapone over three years in patients with Parkinson's disease. Eur J Neurol 2003;10:137-146.
14. Rivera-Calimlim L, Reilly DK. Difference in erythrocyte catechol-O-methyltransferase activity between Orientals and Caucasians: difference in levodopa tolerance. Clin Pharmacol Ther 1984;35:804-809.
15. Rinne UK, Larsen JP, Siden A, et al. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Neurology 1998;51:1309-1314.